Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection

Netanya Utay; Xinyan Zhang; Ronald J. Bosch; Nicholas T. Funderburg; Andrew I. Choi; Janet K. Robinson; Derek M. Fine; Robert W. Coombs; Jeffrey M. Jacobson; Alan L. Landay; Daniel C. Douek; Randall Tressler; Sarah W. Read; Cara C. Wilson; Steven G. Deeks; Michael M. Lederman; Rajesh T. Gandhi

doi:10.1093/infdis/jiu305

Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection

Netanya Utay, Xinyan Zhang, Ronald J. Bosch, Nicholas T. Funderburg, Andrew I. Choi, Janet K. Robinson, Derek M. Fine, Robert W. Coombs, Jeffrey M. Jacobson, Alan L. Landay, Daniel C. Douek, Randall Tressler, Sarah W. Read, Cara C. Wilson, Steven G. Deeks, Michael M. Lederman, Rajesh T. Gandhi

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Abstract

Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.

Original language	English (US)
Pages (from-to)	1549-1554
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	210
Issue number	10
DOIs	https://doi.org/10.1093/infdis/jiu305
State	Published - Nov 15 2014
Externally published	Yes

Keywords

HIV
LDL
LPS
microbial translocation
oxLDL.
sCD14
sevelamer
soluble tissue factor

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/jiu305

Fingerprint

Dive into the research topics of 'Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection'. Together they form a unique fingerprint.

Cite this

Utay, N., Zhang, X., Bosch, R. J., Funderburg, N. T., Choi, A. I., Robinson, J. K., Fine, D. M., Coombs, R. W., Jacobson, J. M., Landay, A. L., Douek, D. C., Tressler, R., Read, S. W., Wilson, C. C., Deeks, S. G., Lederman, M. M., & Gandhi, R. T. (2014). Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection. Journal of Infectious Diseases, 210(10), 1549-1554. https://doi.org/10.1093/infdis/jiu305

Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection. / Utay, Netanya; Zhang, Xinyan; Bosch, Ronald J. et al.
In: Journal of Infectious Diseases, Vol. 210, No. 10, 15.11.2014, p. 1549-1554.

Research output: Contribution to journal › Article › peer-review

Utay, N, Zhang, X, Bosch, RJ, Funderburg, NT, Choi, AI, Robinson, JK, Fine, DM, Coombs, RW, Jacobson, JM, Landay, AL, Douek, DC, Tressler, R, Read, SW, Wilson, CC, Deeks, SG, Lederman, MM & Gandhi, RT 2014, 'Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection', Journal of Infectious Diseases, vol. 210, no. 10, pp. 1549-1554. https://doi.org/10.1093/infdis/jiu305

Utay N, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK et al. Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection. Journal of Infectious Diseases. 2014 Nov 15;210(10):1549-1554. doi: 10.1093/infdis/jiu305

@article{60c88534cf914a4d8affe6c670ba34ae,

title = "Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection",

abstract = "Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.",

keywords = "HIV, LDL, LPS, microbial translocation, oxLDL., sCD14, sevelamer, soluble tissue factor",

author = "Netanya Utay and Xinyan Zhang and Bosch, {Ronald J.} and Funderburg, {Nicholas T.} and Choi, {Andrew I.} and Robinson, {Janet K.} and Fine, {Derek M.} and Coombs, {Robert W.} and Jacobson, {Jeffrey M.} and Landay, {Alan L.} and Douek, {Daniel C.} and Randall Tressler and Read, {Sarah W.} and Wilson, {Cara C.} and Deeks, {Steven G.} and Lederman, {Michael M.} and Gandhi, {Rajesh T.}",

note = "Publisher Copyright: {\textcopyright} The Author 2014.",

year = "2014",

month = nov,

day = "15",

doi = "10.1093/infdis/jiu305",

language = "English (US)",

volume = "210",

pages = "1549--1554",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection

AU - Utay, Netanya

AU - Zhang, Xinyan

AU - Bosch, Ronald J.

AU - Funderburg, Nicholas T.

AU - Choi, Andrew I.

AU - Robinson, Janet K.

AU - Fine, Derek M.

AU - Coombs, Robert W.

AU - Jacobson, Jeffrey M.

AU - Landay, Alan L.

AU - Douek, Daniel C.

AU - Tressler, Randall

AU - Read, Sarah W.

AU - Wilson, Cara C.

AU - Deeks, Steven G.

AU - Lederman, Michael M.

AU - Gandhi, Rajesh T.

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.

AB - Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.

KW - HIV

KW - LDL

KW - LPS

KW - microbial translocation

KW - oxLDL.

KW - sCD14

KW - sevelamer

KW - soluble tissue factor

UR - http://www.scopus.com/inward/record.url?scp=84912144937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912144937&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiu305

DO - 10.1093/infdis/jiu305

M3 - Article

C2 - 24864123

AN - SCOPUS:84912144937

SN - 0022-1899

VL - 210

SP - 1549

EP - 1554

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 10

ER -

Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this